{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:57:35Z","timestamp":1791266255014,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T00:00:00Z","timestamp":1369180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40263-013-0067-9","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T11:50:15Z","timestamp":1369137015000},"page":"457-468","source":"Crossref","is-referenced-by-count":59,"title":["Publication Bias, with a Focus on Psychiatry: Causes and Solutions"],"prefix":"10.1007","volume":"27","author":[{"given":"Erick H.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,5,22]]},"reference":[{"key":"67_CR1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/jama.1990.03440100097014","volume":"263","author":"K Dickersin","year":"1990","unstructured":"Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263:1385\u20139.","journal-title":"JAMA"},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","volume":"86","author":"R Rosenthal","year":"1979","unstructured":"Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638\u201341.","journal-title":"Psychol Bull"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1503\/cmaj.1041086","volume":"171","author":"A-W Chan","year":"2004","unstructured":"Chan A-W, Krleza-Jeri\u0107 K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004;171:735\u201340. doi: 10.1503\/cmaj.1041086 .","journal-title":"CMAJ"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bmj.38356.424606.8F","volume":"330","author":"A-W Chan","year":"2005","unstructured":"Chan A-W, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ. 2005;330:753. doi: 10.1136\/bmj.38356.424606.8F .","journal-title":"BMJ"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1745-6215-13-136","volume":"13","author":"SS Vedula","year":"2012","unstructured":"Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin\u00ae litigation. Trials. 2012;13:136. doi: 10.1186\/1745-6215-13-136 .","journal-title":"Trials"},{"key":"67_CR6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.2010.651","volume":"303","author":"I Boutron","year":"2010","unstructured":"Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303:2058\u201364. doi: 10.1001\/jama.2010.651 .","journal-title":"JAMA"},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11673-010-9208-8","volume":"7","author":"GI Spielmans","year":"2010","unstructured":"Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry. 2010;7:13\u201329. doi: 10.1007\/s11673-010-9208-8 .","journal-title":"Bioethical Inquiry"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1371\/journal.pmed.0050230","volume":"5","author":"A-W Chan","year":"2008","unstructured":"Chan A-W. Bias, spin, and misreporting: time for full access to trial protocols and results. PLoS Med. 2008;5:e230. doi: 10.1371\/journal.pmed.0050230 .","journal-title":"PLoS Med"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaac.2010.10.008","volume":"50","author":"MM Reyes","year":"2011","unstructured":"Reyes MM, Panza KE, Martin A, Bloch MH. Time-lag bias in trials of pediatric antidepressants: a systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2011;50:63\u201372.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.279.4.281","volume":"279","author":"JP Ioannidis","year":"1998","unstructured":"Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281\u20136.","journal-title":"JAMA"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/bmj.315.7109.640","volume":"315","author":"JM Stern","year":"1997","unstructured":"Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315:640\u20135.","journal-title":"BMJ"},{"key":"67_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000270917","volume":"79","author":"GI Spielmans","year":"2010","unstructured":"Spielmans GI, Biehn TL, Sawrey DL. A case study of salami slicing: pooled analyses of duloxetine for depression. Psychother Psychosom. 2010;79:97\u2013106. doi: 10.1159\/000270917 .","journal-title":"Psychother Psychosom"},{"key":"67_CR13","unstructured":"Turner EH (2009) Multiple publication of positive vs. negative trial results in review articles: influence on apparent \u201cweight of the evidence.\u201d In: Sixth International Congress on Peer Review and Biomedical Publication, 2009 Sept 10\u201312, Vancouver, BC, Canada. http:\/\/www.peerreviewcongress.org\/abstracts_2009.html#58 ."},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.291.8.974","volume":"291","author":"E Elm von","year":"2004","unstructured":"von Elm E, Poglia G, Walder B, Tram\u00e8r MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291:974\u201380. doi: 10.1001\/jama.291.8.974 .","journal-title":"JAMA"},{"key":"67_CR15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","volume":"326","author":"H Melander","year":"2003","unstructured":"Melander H. Evidence b(i)ased medicine\u2014selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171\u20133. doi: 10.1136\/bmj.326.7400.1171 .","journal-title":"BMJ"},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/bmj.309.6949.274","volume":"309","author":"Y Ben-Shlomo","year":"1994","unstructured":"Ben-Shlomo Y, Smith GD. \u201cPlace of publication\u201d bias? BMJ. 1994;309:274.","journal-title":"BMJ"},{"key":"67_CR17","first-page":"107","volume":"14","author":"DA Katerndahl","year":"1994","unstructured":"Katerndahl DA. Citation bias: supporting your case in the extreme. Fam Pract Res J. 1994;14:107\u20138.","journal-title":"Fam Pract Res J"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jclinepi.2012.09.015","volume":"66","author":"A-S Jannot","year":"2013","unstructured":"Jannot A-S, Agoritsas T, Gayet-Ageron A, Perneger TV. Citation bias favoring statistically significant studies was present in medical research. J Clin Epidemiol. 2013;66:296\u2013301. doi: 10.1016\/j.jclinepi.2012.09.015 .","journal-title":"J Clin Epidemiol"},{"key":"67_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/00048670802653372","volume":"43","author":"S Chapman","year":"2009","unstructured":"Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry. 2009;43:277\u201382. doi: 10.1080\/00048670802653372 .","journal-title":"Aust N Z J Psychiatry"},{"key":"67_CR20","unstructured":"Carroll L. Alice\u2019s adventures in wonderland. London: Macmillan; 1865."},{"key":"67_CR21","unstructured":"Martinez B. Spitzer charges Glaxo concealed Paxil data. Wall Str J 2004 June 3."},{"key":"67_CR22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","volume":"141","author":"JPA Ioannidis","year":"2004","unstructured":"Ioannidis JPA, Evans SJW, G\u00f8tzsche PC, O\u2019Neill RT, Altman DG, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141:781\u20138.","journal-title":"Ann Intern Med"},{"key":"67_CR23","doi-asserted-by":"crossref","unstructured":"Fanelli D. Negative results are disappearing from most disciplines and countries. Scientometrics. 2012;90(3):891\u2013904.","DOI":"10.1007\/s11192-011-0494-7"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","volume":"358","author":"EH Turner","year":"2008","unstructured":"Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252\u201360.","journal-title":"N Engl J Med"},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(04)16043-1","volume":"363","author":"CJ Whittington","year":"2004","unstructured":"Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341\u20135. doi: 10.1016\/S0140-6736(04)16043-1 .","journal-title":"Lancet"},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00004583-200107000-00010","volume":"40","author":"MB Keller","year":"2001","unstructured":"Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762\u201372. doi: 10.1097\/00004583-200107000-00010 .","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"67_CR27","doi-asserted-by":"crossref","unstructured":"Jureidini J, Tonkin A. Paroxetine in major depression. J Am Acad Child Adolesc Psychiatry. 2003;42:514 (author reply 514\u20135). doi: 10.1097\/01.CHI.0000046825.95464.DA .","DOI":"10.1097\/01.CHI.0000046825.95464.DA"},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JRS-2008-0426","volume":"20","author":"J Jureidini","year":"2008","unstructured":"Jureidini J, McHenry L, Mansfield P. Clinical trials and drug promotion: Selective reporting of study 329. Int J Risk Saf Med. 2008;20:73\u201381.","journal-title":"Int J Risk Saf Med"},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","volume":"341","author":"D Eyding","year":"2010","unstructured":"Eyding D, Lelgemann M, Grouven U, H\u00e4rter M, Kromp M, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 2010;341:c4737.","journal-title":"BMJ"},{"key":"67_CR30","doi-asserted-by":"crossref","first-page":"c6487","DOI":"10.1136\/bmj.c6487","volume":"341","author":"EH Turner","year":"2010","unstructured":"Turner EH. Reboxetine in depression. All the relevant data? BMJ. 2010;341:c6487.","journal-title":"BMJ"},{"key":"67_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3928\/02793695-20110809-01","volume":"49","author":"RH Howland","year":"2011","unstructured":"Howland RH. Publication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv. 2011;49:11\u20134. doi: 10.3928\/02793695-20110809-01 .","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"67_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","volume":"163","author":"S Heres","year":"2006","unstructured":"Heres S, Davis J, Maino K, Jetzinger E, Kissling W, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185\u201394. doi: 10.1176\/appi.ajp.163.2.185 .","journal-title":"Am J Psychiatry"},{"key":"67_CR33","doi-asserted-by":"crossref","unstructured":"Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration Database. PLoS Med. 2012;9:e1001189. doi: 10.1371\/journal.pmed.1001189 . http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1001189 .","DOI":"10.1371\/journal.pmed.1001189"},{"key":"67_CR34","doi-asserted-by":"crossref","unstructured":"Tsai A, Rosenlicht N, Jureidini J, Parry P. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med, 2011;8:e1000434. http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1000434 .","DOI":"10.1371\/journal.pmed.1000434"},{"key":"67_CR35","first-page":"211","volume":"10","author":"S Nassir Ghaemi","year":"2008","unstructured":"Nassir Ghaemi S, Shirzadi AA, Filkowski M. Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. Medscape J Med. 2008;10:211.","journal-title":"Medscape J Med"},{"key":"67_CR36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ebmh.12.3.65","volume":"12","author":"SN Ghaemi","year":"2009","unstructured":"Ghaemi SN. The failure to know what isn\u2019t known: negative publication bias with lamotrigine and a glimpse inside peer review. Evid Based Ment Health. 2009;12:65\u20138.","journal-title":"Evid Based Ment Health"},{"key":"67_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","volume":"60","author":"JR Calabrese","year":"1999","unstructured":"Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79\u201388.","journal-title":"J Clin Psychiatry"},{"key":"67_CR38","doi-asserted-by":"crossref","unstructured":"Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. PLoS Med. 2013;10:e1001378. doi: 10.1371\/journal.pmed.1001378 . http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.1001378 .","DOI":"10.1371\/journal.pmed.1001378"},{"key":"67_CR39","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.4088\/JCP.12m07794","volume":"73","author":"MJ Chace","year":"2012","unstructured":"Chace MJ, Zhang F, Fullerton CA, Huskamp HA, Gilden D, et al. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. J Clin Psychiatry. 2012;73:1388\u201394. doi: 10.4088\/JCP.12m07794 .","journal-title":"J Clin Psychiatry"},{"key":"67_CR40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MLR.0b013e3181ca404e","volume":"48","author":"CA Fullerton","year":"2010","unstructured":"Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care. 2010;48:372\u20139. doi: 10.1097\/MLR.0b013e3181ca404e .","journal-title":"Med Care"},{"key":"67_CR41","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","volume":"361","author":"SS Vedula","year":"2009","unstructured":"Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361:1963\u201371. doi: 10.1056\/NEJMsa0906126 .","journal-title":"N Engl J Med"},{"key":"67_CR42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp0808659","volume":"360","author":"CS Landefeld","year":"2009","unstructured":"Landefeld CS, Steinman MA. The Neurontin legacy\u2014marketing through misinformation and manipulation. N Engl J Med. 2009;360:103\u20136. doi: 10.1056\/NEJMp0808659 .","journal-title":"N Engl J Med"},{"key":"67_CR43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","volume":"145","author":"MA Steinman","year":"2006","unstructured":"Steinman MA, Bero LA, Chren M-M, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284\u201393.","journal-title":"Ann Intern Med"},{"key":"67_CR44","doi-asserted-by":"crossref","first-page":"e1301","DOI":"10.1542\/peds.2011-3285","volume":"129","author":"M Carrasco","year":"2012","unstructured":"Carrasco M, Volkmar FR, Bloch MH. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias. Pediatrics. 2012;129:e1301\u201310. doi: 10.1542\/peds.2011-3285 .","journal-title":"Pediatrics"},{"key":"67_CR45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","volume":"11","author":"N McGauran","year":"2010","unstructured":"McGauran N, Wieseler B, Kreis J, Sch\u00fcler Y-B, K\u00f6lsch H, et al. Reporting bias in medical research\u2014a narrative review. Trials. 2010;11:37. doi: 10.1186\/1745-6215-11-37 .","journal-title":"Trials"},{"key":"67_CR46","doi-asserted-by":"crossref","unstructured":"Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008;5:e217 (discussion e217). doi: 10.1371\/journal.pmed.0050217 . http:\/\/www.plosmedicine.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pmed.0050217 .","DOI":"10.1371\/journal.pmed.0050217"},{"key":"67_CR47","doi-asserted-by":"crossref","first-page":"d7202","DOI":"10.1136\/bmj.d7202","volume":"344","author":"B Hart","year":"2012","unstructured":"Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202. doi: 10.1136\/bmj.d7202 .","journal-title":"BMJ"},{"key":"67_CR48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/485298a","volume":"485","author":"E Yong","year":"2012","unstructured":"Yong E. Replication studies: bad copy. Nature. 2012;485:298\u2013300. doi: 10.1038\/485298a .","journal-title":"Nature"},{"key":"67_CR49","unstructured":"Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2005."},{"key":"67_CR50","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/bmj.39575.675787.651","volume":"336","author":"R Moynihan","year":"2008","unstructured":"Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336:1402\u20133. doi: 10.1136\/bmj.39575.675787.651 .","journal-title":"BMJ"},{"key":"67_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/0272989X9801800215","volume":"18","author":"DG Kern","year":"1998","unstructured":"Kern DG. Confidentiality agreements and scientific independence. Med Decis Making. 1998;18:239.","journal-title":"Med Decis Making"},{"key":"67_CR52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1745-6215-12-9","volume":"12","author":"PA Rochon","year":"2011","unstructured":"Rochon PA, Sekeres M, Hoey J, Lexchin J, Ferris LE, et al. Investigator experiences with financial conflicts of interest in clinical trials. Trials. 2011;12:9. doi: 10.1186\/1745-6215-12-9 .","journal-title":"Trials"},{"key":"67_CR53","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005053-200209000-00002","volume":"190","author":"DJ Safer","year":"2002","unstructured":"Safer DJ. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J Nerv Ment Dis. 2002;190:583\u201392.","journal-title":"J Nerv Ment Dis"},{"key":"67_CR54","doi-asserted-by":"crossref","unstructured":"Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. doi: 10.1002\/14651858.MR000033.pub2 .","DOI":"10.1002\/14651858.MR000033.pub2"},{"key":"67_CR55","unstructured":"Dickersin K, Min YI. NIH clinical trials and publication bias. Online J Curr Clin Trials 1993;50."},{"key":"67_CR56","doi-asserted-by":"crossref","first-page":"d7292","DOI":"10.1136\/bmj.d7292","volume":"344","author":"JS Ross","year":"2012","unstructured":"Ross JS, Tse T, Zarin DA, Xu H, Zhou L, et al. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis. BMJ. 2012;344:d7292. doi: 10.1136\/bmj.d7292 .","journal-title":"BMJ"},{"key":"67_CR57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jclinepi.2011.03.013","volume":"64","author":"GA Matthews","year":"2011","unstructured":"Matthews GA, Dumville JC, Hewitt CE, Torgerson DJ. Retrospective cohort study highlighted outcome reporting bias in UK publicly funded trials. J Clin Epidemiol. 2011;64:1317\u201324. doi: 10.1016\/j.jclinepi.2011.03.013 .","journal-title":"J Clin Epidemiol"},{"key":"67_CR58","doi-asserted-by":"crossref","unstructured":"Fanelli D. Do pressures to publish increase scientists\u2019 bias? An empirical support from US States Data. PLoS ONE. 2010;5:e10271. doi: 10.1371\/journal.pone.0010271 . http:\/\/www.plosone.org\/article\/info:doi\/10.1371\/journal.pone.0010271 .","DOI":"10.1371\/journal.pone.0010271"},{"key":"67_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1521\/soco.2007.25.1.1","volume":"25","author":"H Blank","year":"2007","unstructured":"Blank H, Musch J, Pohl R. Hindsight bias: on being wise after the event. Soc Cognit. 2007;25:1.","journal-title":"Soc Cognit"},{"key":"67_CR60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1207\/s15327957pspr0203_4","volume":"2","author":"N Kerr","year":"1998","unstructured":"Kerr N. HARKing: hypothesizing after the results are known. Person Soc Psychol Rev. 1998;2:196.","journal-title":"Person Soc Psychol Rev"},{"key":"67_CR61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/bies.201190000","volume":"33","author":"A Moore","year":"2011","unstructured":"Moore A. Prose and principle: getting your message across: more than detailed cataloguing of research findings, emphasis of principles within a narrative engages the readers of reviews. Bioessays. 2011;33:85. doi: 10.1002\/bies.201190000 .","journal-title":"Bioessays"},{"key":"67_CR62","doi-asserted-by":"crossref","unstructured":"Bacon F. In: Jardine L, Silverthorne M, editors. The new organon. Cambridge: Cambridge University Press; 2000.","DOI":"10.1017\/CBO9781139164030"},{"key":"67_CR63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.pra.0000367774.11260.e4","volume":"16","author":"M Makhinson","year":"2010","unstructured":"Makhinson M. Biases in medication prescribing: the case of second-generation antipsychotics. J Psychiatr Pract. 2010;16:15\u201321. doi: 10.1097\/01.pra.0000367774.11260.e4 .","journal-title":"J Psychiatr Pract"},{"key":"67_CR64","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jama.1990.03440100121018","volume":"263","author":"I Chalmers","year":"1990","unstructured":"Chalmers I. Underreporting research is scientific misconduct. JAMA. 1990;263:1405\u20138.","journal-title":"JAMA"},{"key":"67_CR65","doi-asserted-by":"crossref","first-page":"e1000326","DOI":"10.1371\/journal.pmed.1000326","volume":"7","author":"H Bastian","year":"2010","unstructured":"Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7:e1000326. doi: 10.1371\/journal.pmed.1000326 .","journal-title":"PLoS Med"},{"key":"67_CR66","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/asi.21226","volume":"61","author":"V Lariviere","year":"2010","unstructured":"Lariviere V, Gingras Y. The impact factor\u2019s Matthew effect: a natural experiment in bibliometrics. J Am Soc Inf Sci Technol. 2010;61:424\u20137.","journal-title":"J Am Soc Inf Sci Technol"},{"key":"67_CR67","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/archinternmed.2010.406","volume":"170","author":"GB Emerson","year":"2010","unstructured":"Emerson GB, Warme WJ, Wolf FM, Heckman JD, Brand RA, et al. Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial. Arch Intern Med. 2010;170:1934\u20139. doi: 10.1001\/archinternmed.2010.406 .","journal-title":"Arch Intern Med"},{"key":"67_CR68","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/ije\/dyr095","volume":"40","author":"KC Siontis","year":"2011","unstructured":"Siontis KC, Evangelou E, Ioannidis JP. Magnitude of effects in clinical trials published in high-impact general medical journals. Int J Epidemiol. 2011;40:1280\u201391. doi: 10.1093\/ije\/dyr095 .","journal-title":"Int J Epidemiol"},{"key":"67_CR69","doi-asserted-by":"crossref","unstructured":"Horton R. The refiguration of medical thought. Lancet. 2000;356:2\u20134. http:\/\/www.thelancet.com\/lancet-information-for-authors\/article-types-manuscript-requirements .","DOI":"10.1016\/S0140-6736(00)02420-X"},{"key":"67_CR70","doi-asserted-by":"crossref","unstructured":"Evangelou E, Siontis KC, Pfeiffer T, Ioannidis JPA. Perceived information gain from randomized trials correlates with publication in high-impact factor journals. J Clin Epidemiol. 2012;65(12):1274\u201381. doi: 10.1016\/j.jclinepi.2012.06.009 .","DOI":"10.1016\/j.jclinepi.2012.06.009"},{"key":"67_CR71","doi-asserted-by":"crossref","unstructured":"Lundh A, Barbateskovic M, Hr\u00f3bjartsson A, G\u00f8tzsche P. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue\u2014cohort study. PLoS Med. 2010;7:e1000354EP.","DOI":"10.1371\/journal.pmed.1000354"},{"key":"67_CR72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/10543409708835206","volume":"7","author":"MF Huque","year":"1997","unstructured":"Huque MF, Sankoh AJ. A reviewer\u2019s perspective on multiple endpoint issues in clinical trials. J Biopharm Stat. 1997;7:545\u201364.","journal-title":"J Biopharm Stat"},{"key":"67_CR73","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jclinepi.2006.01.012","volume":"59","author":"PC Austin","year":"2006","unstructured":"Austin PC, Mamdani MM, Juurlink DN, Hux JE. Testing multiple statistical hypotheses resulted in spurious associations: a study of astrological signs and health. J Clin Epidemiol. 2006;59:964\u20139. doi: 10.1016\/j.jclinepi.2006.01.012 .","journal-title":"J Clin Epidemiol"},{"key":"67_CR74","unstructured":"Kubler-Ross E. On death and dying. New York: Scribner; 2011."},{"key":"67_CR75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"67_CR76","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139.","journal-title":"Br J Psychiatry"},{"key":"67_CR77","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1176\/appi.ajp.161.12.2163","volume":"161","author":"RM Bagby","year":"2004","unstructured":"Bagby RM. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry. 2004;161:2163\u201377. doi: 10.1176\/appi.ajp.161.12.2163 .","journal-title":"Am J Psychiatry"},{"key":"67_CR78","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archpsyc.1988.01800320058007","volume":"45","author":"JB Williams","year":"1988","unstructured":"Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR79","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.biopsych.2008.04.036","volume":"64","author":"AA Nierenberg","year":"2008","unstructured":"Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008;64:455\u201360. doi: 10.1016\/j.biopsych.2008.04.036 .","journal-title":"Biol Psychiatry"},{"key":"67_CR80","first-page":"235","volume":"27","author":"R McIntyre","year":"2002","unstructured":"McIntyre R, Kennedy S, Bagby RM, Bakish D. Assessing full remission. J Psychiatry Neurosci. 2002;27:235\u20139.","journal-title":"J Psychiatry Neurosci"},{"key":"67_CR81","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0447.1981.tb00676.x","volume":"63","author":"P Bech","year":"1981","unstructured":"Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, et al. The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63:290\u20139.","journal-title":"Acta Psychiatr Scand"},{"key":"67_CR82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0447.1997.tb09649.x","volume":"95","author":"RL O\u2019Sullivan","year":"1997","unstructured":"O\u2019Sullivan RL, Fava M, Agustin C, Baer L, Rosenbaum JF. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand. 1997;95:379\u201384.","journal-title":"Acta Psychiatr Scand"},{"key":"67_CR83","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/0956797611417632","volume":"22","author":"JP Simmons","year":"2011","unstructured":"Simmons JP, Nelson LD, Simonsohn U. False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. Psychol Sci. 2011;22:1359\u201366. doi: 10.1177\/0956797611417632 .","journal-title":"Psychol Sci"},{"key":"67_CR84","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","volume":"48","author":"E Frank","year":"1991","unstructured":"Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851\u20135.","journal-title":"Arch Gen Psychiatry"},{"key":"67_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004850-200401000-00001","volume":"19","author":"M Zimmerman","year":"2004","unstructured":"Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery\u2013Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol. 2004;19:1.","journal-title":"Int Clin Psychopharmacol"},{"key":"67_CR86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","volume":"19","author":"M Fava","year":"1996","unstructured":"Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179\u2013200.","journal-title":"Psychiatr Clin North Am"},{"issue":"Suppl 16","key":"67_CR87","first-page":"5","volume":"62","author":"AA Nierenberg","year":"2001","unstructured":"Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):5\u20139.","journal-title":"J Clin Psychiatry"},{"key":"67_CR88","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.39468.610775.DB","volume":"336","author":"J Lenzer","year":"2008","unstructured":"Lenzer J. Unreported cholesterol drug data released by company. BMJ. 2008;336:180\u20131. doi: 10.1136\/bmj.39468.610775.DB .","journal-title":"BMJ"},{"key":"67_CR89","doi-asserted-by":"crossref","unstructured":"Turner E. Correction\/clarification about FDA review documents. PLoS Med. 2005;2:e422 (author reply e423). doi: 10.1371\/journal.pmed.0020422 .","DOI":"10.1371\/journal.pmed.0020422"},{"key":"67_CR90","doi-asserted-by":"crossref","unstructured":"Turner EH. A taxpayer-funded clinical trials registry and results database. PLoS Med. 2004;1:e60. http:\/\/www.plosmedicine.org\/article\/info:doi\/10.1371\/journal.pmed.0010060 .","DOI":"10.1371\/journal.pmed.0010060"},{"key":"67_CR91","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","volume":"19","author":"O Siddiqui","year":"2009","unstructured":"Siddiqui O, Hung HMJ, O\u2019Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009;19:227\u201346. doi: 10.1080\/10543400802609797 .","journal-title":"J Biopharm Stat"},{"key":"67_CR92","unstructured":"Office of New Drugs. Good review practice: attachment A: annotated clinical review template. 2010. http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/ManualofPoliciesProcedures\/UCM236903.pdf ."},{"key":"67_CR93","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Guideline for industry, structure and content of clinical study reports\u2014ICH E3. 1996. p. 25\u201335. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm078749.pdf ."},{"key":"67_CR94","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMsa1012065","volume":"364","author":"DA Zarin","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database\u2014update and key issues. N Engl J Med. 2011;364:852\u201360. doi: 10.1056\/NEJMsa1012065 .","journal-title":"N Engl J Med"},{"key":"67_CR95","unstructured":"US Food and Drug Administration. Food and Drug Modernization Act of 1997 (FDAMA). 1997. p. 2295. http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-105publ115\/html\/PLAW-105publ115.htm ."},{"key":"67_CR96","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1056\/NEJMsa053234","volume":"353","author":"DA Zarin","year":"2005","unstructured":"Zarin DA, Tse T, Ide NC. Trial Registration at ClinicalTrials.gov between May and October 2005. N Engl J Med. 2005;353:2779\u201387. doi: 10.1056\/NEJMsa053234 .","journal-title":"N Engl J Med"},{"key":"67_CR97","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMp048286","volume":"351","author":"EJ Topol","year":"2004","unstructured":"Topol EJ. Failing the public health\u2014rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351:1707\u20139.","journal-title":"N Engl J Med"},{"key":"67_CR98","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.292.11.1363","volume":"292","author":"CD DeAngelis","year":"2004","unstructured":"DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292:1363\u20134. doi: 10.1001\/jama.292.11.1363 .","journal-title":"JAMA"},{"key":"67_CR99","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/jama.2012.4230","volume":"307","author":"K Dickersin","year":"2012","unstructured":"Dickersin K, Rennie D. The evolution of trial registries and their use to assess the clinical trial enterprise. JAMA. 2012;307:1861\u20134. doi: 10.1001\/jama.2012.4230 .","journal-title":"JAMA"},{"key":"67_CR100","doi-asserted-by":"crossref","first-page":"e14701","DOI":"10.1371\/journal.pone.0014701","volume":"6","author":"RF Viergever","year":"2011","unstructured":"Viergever RF, Ghersi D. The quality of registration of clinical trials. PLoS ONE. 2011;6:e14701. doi: 10.1371\/journal.pone.0014701.t003 .","journal-title":"PLoS ONE"},{"key":"67_CR101","unstructured":"Dodd C. Fair access to Clinical Trials Act (FACT). 2005. http:\/\/olpa.od.nih.gov\/tracking\/109\/senate_bills\/session1\/s-470.asp ."},{"key":"67_CR102","unstructured":"Dingell J. Food and Drug Administration Amendments Act of 2007 (FDAAA). 2007. http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf ."},{"key":"67_CR103","doi-asserted-by":"crossref","first-page":"d7373","DOI":"10.1136\/bmj.d7373","volume":"344","author":"AP Prayle","year":"2012","unstructured":"Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ. 2012;344:d7373. doi: 10.1136\/bmj.d7373 .","journal-title":"BMJ"},{"key":"67_CR104","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1126\/science.1153632","volume":"319","author":"DA Zarin","year":"2008","unstructured":"Zarin DA, Tse T. Moving toward transparency of clinical trials. Science. 2008;319:1340\u20132. doi: 10.1126\/science.1153632 .","journal-title":"Science"},{"key":"67_CR105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.322.5898.44c","volume":"322","author":"EH Turner","year":"2008","unstructured":"Turner EH. Closing a loophole in the FDA Amendments Act. Science. 2008;322:44\u20136.","journal-title":"Science"},{"key":"67_CR106","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1378\/chest.08-3022","volume":"136","author":"T Tse","year":"2009","unstructured":"Tse T, Williams RJ, Zarin DA. Reporting \u201cbasic results\u201d in ClinicalTrials.gov. Chest. 2009;136:295\u2013303. doi: 10.1378\/chest.08-3022 .","journal-title":"Chest"},{"key":"67_CR107","unstructured":"Veitch E (2012) Silent takedown of the pharma trials database\u2026and more. Speaking of Medicine. 2012 March 23. http:\/\/blogs.plos.org\/speakingofmedicine\/2012\/03\/23\/silent-takedown-of-the-pharma-trials-database%E2%80%A6and-more\/ (accessed 22 Nov 2012)."},{"key":"67_CR108","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mayocp.2012.02.009","volume":"87","author":"BA Mansi","year":"2012","unstructured":"Mansi BA, Clark J, David FS, Gesell TM, Glasser S, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc. 2012;87:424\u20139. doi: 10.1016\/j.mayocp.2012.02.009 .","journal-title":"Mayo Clin Proc"},{"key":"67_CR109","unstructured":"GlaxoSmithKline (2013) GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges. http:\/\/www.gsk.com\/media\/press-releases\/2012\/GSK-announces-further-initiatives-to-tackle-global-health-challenges.html ."},{"key":"67_CR110","unstructured":"GlaxoSmithKline (2013) GSK announces support for AllTrials campaign for clinical data transparency. http:\/\/www.gsk.com\/media\/press-releases\/2013\/GSK-announces-support-forAll-Trials-campaign-for-clinical-data-transparency.html ."},{"key":"67_CR111","doi-asserted-by":"crossref","unstructured":"Kmietowicz Z. Roche says it will not relinquish control over access to clinical trial data. BMJ. 2013;346.","DOI":"10.1136\/bmj.f1374"},{"key":"67_CR112","author":"AK Asamoah","year":"2010","unstructured":"Asamoah AK, Sharfstein JM. Transparency at the Food and Drug Administration. N Engl J Med. 2010:362(25):2341-3;. doi: 10.1056\/NEJMp1005202 .","journal-title":"N Engl J Med"},{"key":"67_CR113","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","volume":"18","author":"H Melander","year":"2008","unstructured":"Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. A regulatory Apologia\u2014a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008;18:623\u20137. doi: 10.1016\/j.euroneuro.2008.06.003 .","journal-title":"Eur Neuropsychopharmacol"},{"key":"67_CR114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0031-1271704","volume":"44","author":"V Henkel","year":"2011","unstructured":"Henkel V, Seem\u00fcller F, Obermeier M, Adli M, Bauer M, et al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry. 2011;44:27\u201332. doi: 10.1055\/s-0030-1267177 .","journal-title":"Pharmacopsychiatry"},{"key":"67_CR115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2012.03.021","volume":"141","author":"V Henkel","year":"2012","unstructured":"Henkel V, Casaulta F, Seem\u00fcller F, Kr\u00e4henb\u00fchl S, Obermeier M, et al. Study design features affecting outcome in antidepressant trials. J Affect Disord. 2012;141:160\u20137. doi: 10.1016\/j.jad.2012.03.021 .","journal-title":"J Affect Disord"},{"key":"67_CR116","doi-asserted-by":"crossref","first-page":"d2686","DOI":"10.1136\/bmj.d2686","volume":"342","author":"PC G\u00f8tzsche","year":"2011","unstructured":"G\u00f8tzsche PC, J\u00f8rgensen AW. Opening up data at the European Medicines Agency. BMJ. 2011;342:d2686.","journal-title":"BMJ"},{"key":"67_CR117","doi-asserted-by":"crossref","first-page":"e1001202","DOI":"10.1371\/journal.pmed.1001202","volume":"9","author":"H-G Eichler","year":"2012","unstructured":"Eichler H-G, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? A view from regulators. PLoS Med. 2012;9:e1001202. doi: 10.1371\/journal.pmed.1001202 .","journal-title":"PLoS Med"},{"key":"67_CR118","unstructured":"European Medicines Agency EMEA. Workshop on access to clinical-trial data and transparency kicks off process towards proactive publication of data. emeaeuropaeu. 2012. http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/11\/news_detail_001662.jsp&mid=WC0b01ac058004d5c1 . accessed 28 Nov 2012."},{"key":"67_CR119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/2046-4053-1-50","volume":"1","author":"B Wieseler","year":"2012","unstructured":"Wieseler B, McGauran N, Kerekes MF, Kaiser T. Access to regulatory data from the European Medicines Agency: the times they are a-changing. Syst Rev. 2012;1:50. doi: 10.1136\/bmj.329.7477.1253 .","journal-title":"Syst Rev"},{"key":"67_CR120","unstructured":"International Committee of Journal Editors ICMJE. Obligation to publish negative studies. http:\/\/www.icmje.org\/publishing_1negative.html . Accessed on 10 April 2013."},{"key":"67_CR121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1503\/jpn.120065","volume":"37","author":"R Joober","year":"2012","unstructured":"Joober R, Schmitz N, Annable L, Boksa P. Publication bias: what are the challenges and can they be overcome? J Psychiatry Neurosci. 2012;37:149\u201352. doi: 10.1503\/jpn.120065 .","journal-title":"J Psychiatry Neurosci"},{"key":"67_CR122","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archinternmed.2009.100","volume":"169","author":"L Sridharan","year":"2009","unstructured":"Sridharan L, Greenland P. Editorial policies and publication bias: the importance of negative studies. Arch Intern Med. 2009;169:1022\u20133. doi: 10.1001\/archinternmed.2009.100 .","journal-title":"Arch Intern Med"},{"key":"67_CR123","doi-asserted-by":"crossref","unstructured":"Mirkin JN, Bach PB. Outcome-blinded peer review. Arch Intern Med. 2011;171:1213\u20134 (author reply 1214). doi: 10.1001\/archinternmed.2011.56 .","DOI":"10.1001\/archinternmed.2011.56"},{"key":"67_CR124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0447.2010.01650.x","volume":"123","author":"F Colom","year":"2011","unstructured":"Colom F, Vieta E. The need for publishing the silent evidence from negative trials. Acta Psychiatr Scand. 2011;123:91\u20134.","journal-title":"Acta Psychiatr Scand"},{"key":"67_CR125","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"key":"67_CR126","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","volume":"340","author":"JJ Kirkham","year":"2010","unstructured":"Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ. 2010;340:c365.","journal-title":"BMJ"},{"key":"67_CR127","doi-asserted-by":"crossref","unstructured":"Senn S. Misunderstanding publication bias: editors are not blameless after all. F1000 Res. 2012. doi: 10.3410\/f1000research.1-59.v1 .","DOI":"10.3410\/f1000research.1-59.v1"},{"key":"67_CR128","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JPA Ioannidis","year":"2005","unstructured":"Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2:e124. doi: 10.1371\/journal.pmed.0020124 .","journal-title":"PLoS Med"},{"key":"67_CR129","doi-asserted-by":"crossref","unstructured":"Mathieu S, Chan A-W, Ravaud P. Use of trial register information during the peer review process. PLoS ONE. 2013;8:e59910. doi: 10.1371\/journal.pone.0059910 . http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0059910 .","DOI":"10.1371\/journal.pone.0059910"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0067-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0067-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0067-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T23:37:14Z","timestamp":1595806634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0067-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,22]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0067-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,22]]}}}